Review of COVID‑19 Vaccine

  • Oluwafemi Efuntoye
  • Olufemi Obafemi
  • Olumuyiwa Folayan
  • Abimbola Amoo
  • Habeeb D. Ogundipe
  • Ugo Enebeli
  • Kehinde Kanmodi
  • Toluwani Olalere
  • Lawson Obazenu
  • Oladimeji Adebayo
Keywords: COVID‑19, pandemics, vaccine

Abstract

Coronavirus disease 2019 (COVID‑19) accounts for over 92 million confirmed cases worldwide, with over 2.06 million deaths. In the past year, more than 290 candidate vaccines have been tested; COVID‑19 vaccine  development was sped up, with shortened timeline, due to the urgent global need in the face of the pandemic. In addition, people with the highest risk of contracting the disease, such as health workers with a high risk of exposure, elderlies, and people with underlying comorbidities, were prioritized with vaccination rollout. The article narratively reviewed original and review articles available on PubMed and Google Scholar related to the theme to provide up‑to‑date information. The different templates developed and studied for COVID‑19 vaccines include the whole‑virus vaccine, viral vector vaccine, nucleic acid (deoxyribonucleic acid and ribonucleic acid), and protein subunit vaccine. Myths impede vaccine uptake in this part of the globe. Adopting these myths leads to sharing and spreading, which negatively impacts the prevention of COVID‑19 and vaccine uptake. Adverse event following immunizations (AEFIs) is classified based on severity, from minor to severe. The minor ones are common events that pose no potential health risks to the receiver of the vaccine. The type determines the safety profile, severity, and frequency of AEFIs observed with the vaccine administration. Overall, this pandemic
has heightened the global level of threat awareness; it has also provided motivation to prepare for future  pandemics by developing new vaccines.

Published
2021-08-24
Section
Articles

Journal Identifiers


eISSN: 2667-0526
print ISSN: 1115-2613